Berlin-Chemie/Menarini Pharma GmbH Sustainability Profile
Berlin-Chemie/Menarini Pharma GmbH, headquartered in Berlin, Germany, is a prominent player in the pharmaceutical industry, specialising in the development and marketing of innovative medicines. Founded in 1886, the company has established a strong presence across Europe and beyond, focusing on therapeutic areas such as cardiology, oncology, and diabetes care. With a commitment to research and development, Berlin-Chemie offers a diverse portfolio of prescription medications and over-the-counter products that stand out for their efficacy and safety. The company is recognised for its strategic partnerships and collaborations, which have bolstered its market position and expanded its reach. Notable achievements include a robust pipeline of new therapies and a reputation for quality that resonates with healthcare professionals and patients alike.
DitchCarbon Score
How does Berlin-Chemie/Menarini Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Berlin-Chemie/Menarini Pharma GmbH's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Berlin-Chemie/Menarini Pharma GmbH's reported carbon emissions
Berlin-Chemie/Menarini Pharma GmbH, headquartered in Germany (DE), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges available for the company. As a current subsidiary, Berlin-Chemie/Menarini Pharma GmbH may inherit climate commitments and emissions data from its parent organisation, but no specific details have been provided regarding such cascaded information. The company appears to be in the early stages of establishing its climate strategy, with no clear initiatives or targets outlined at this time. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, and it is anticipated that Berlin-Chemie/Menarini Pharma GmbH will align with these trends in the future.
How Carbon Intensive is Berlin-Chemie/Menarini Pharma GmbH's Industry?
How Carbon Intensive is Berlin-Chemie/Menarini Pharma GmbH's Location?
Berlin-Chemie/Menarini Pharma GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Berlin-Chemie/Menarini Pharma GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
